Kyntra Bio reports Q2 2026 results, reaffirms fourth-quarter trial milestones

Kyntra Bio reported second quarter 2026 results on August 13, 2026, with two clinical programs still central to its plans for the rest of the year. Enrollment continues in the Phase 2 monotherapy trial of FG-3246, an antibody drug conjugate targeting CD46 in metastatic castration-resistant prostate cancer, with an interim analysis on track for the fourth quarter of 2026.¹

The pivotal Phase 3 trial protocol for roxadustat, aimed at treating anemia in patients with lower-risk myelodysplastic syndromes and high transfusion burden, has now been finalized.¹ Kyntra Bio's CEO, Thane Wettig, said the company remains focused on starting that pivotal trial and completing the FG-3246 interim analysis, both targeted for the fourth quarter of this year.

The company also presented additional data from the Phase 3 MATTERHORN study at the European Hematology Association Congress 2026, showing in a post hoc analysis that roxadustat-treated patients with high transfusion burden had better transfusion independence than placebo, with similar rates seen regardless of ring sideroblast status.¹ Kyntra Bio said it is still weighing whether to develop roxadustat on its own or through a partnership, while continuing to target a fourth-quarter 2026 start for the Phase 3 trial.¹

On financials, Kyntra Bio held $95.7 million in cash, cash equivalents, investments, and accounts receivable as of June 30, 2026.¹ The company said this is expected to fund its operating plans into 2028.¹ Net income from continuing operations for the quarter was $12.0 million, or $2.96 per basic and diluted share, compared with a net loss of $13.7 million, or $3.38 per share, in the same quarter last year.¹